

Appendix 2: Full-Text Screening Checklist

Reviewer: _____ Date: _____

Ref ID: _____ Author: _____	Publication Year: _____		
Did the study include:	Yes (Include)	Unclear (Include) ^a	No (Exclude)
1) Non-pregnant, treatment-naive adults with unknown liver enzyme values?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2) Q1 to Q4: Any screening program for HCV infection? Q5 (clinical validity): Ab or Ag test?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3) Q1 to Q4: A comparison with no screening? Q5 (clinical validity): PCR diagnostic test?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4) Any of the following as the study outcomes? Q1 (clinical effectiveness) <ul style="list-style-type: none"> • Mortality due to HCV infection • Morbidity due to HCV infection (e.g., cirrhosis [compensated or decompensated] and HCC) • Rate of liver transplantation • Quality of life • Reduced HCV transmission • Sustained or improved virologic response • Behavioural changes to improve health outcomes • Histological improvements. Q2 (harms) <ul style="list-style-type: none"> • Over-diagnosis • Over-treatment • False-positives • False-negatives • Harms of follow-up tests (including biopsy) • Insurance premiums • Labelling • Abuse or violence • Anxiety • Partner discord Q3 (cost-effectiveness) <ul style="list-style-type: none"> • CEA outcomes (e.g., ICER, ICUR, CBR) • Budget impact analysis outcomes Q4 (patients' preferences) Patients' preferences and values regarding HCV screening; for example: <ul style="list-style-type: none"> • Willingness to be screened • Factors considered in decisions to be screened 	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Ref ID: _____	Author: _____	Publication Year: _____		
Did the study include:	Yes (Include)	Unclear (Include) ^a	No (Exclude)	
Q5 (clinical validity) <ul style="list-style-type: none"> Ab+RNA+ Ab–RNA+ Ab+RNA– Ab–RNA– 				
5) Any of the following study designs? Q1 (clinical effectiveness), Q2 (harms) <ul style="list-style-type: none"> RCT Non-randomized study with a comparator group Non-randomized study without a comparator group Disease-progression modelling study Q3 (cost-effectiveness) <ul style="list-style-type: none"> RCT Economic evaluation Modelling study Q4 (patients' preferences) <ul style="list-style-type: none"> Qualitative study Survey Mixed-methods study Q5 (clinical validity) <ul style="list-style-type: none"> Cross-sectional study 	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
6) Conducted in a primary care setting, setting generalizable to primary care, or other setting in which screening is commonly performed (e.g., emergency department, urgent care unit)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
7) Conducted in the following country settings? Q3 (cost-effectiveness) <ul style="list-style-type: none"> Canada Q5 (clinical validity) <ul style="list-style-type: none"> Low-to-moderate HCV prevalence country 	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
8) Published in English or French?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Decision to include the study in the review:	Yes <input type="checkbox"/>		No <input type="checkbox"/>	
Reason(s) for exclusion:	<input type="checkbox"/> Inappropriate study population <input type="checkbox"/> No intervention of interest <input type="checkbox"/> No/inappropriate comparator ^b <input type="checkbox"/> No relevant outcomes <input type="checkbox"/> Irrelevant study type <input type="checkbox"/> Irrelevant language of publication <input type="checkbox"/> Not primary report of study <input type="checkbox"/> Study description only <input type="checkbox"/> Other:			

Ab = antibody; Ag = antigen; CBR = cost-benefit ratio; CEA = cost-effectiveness analysis; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; ICER = incremental cost-effectiveness ratio; ICUR = incremental cost-utility ratio; ID = identification; PCR = polymerase chain reaction; Q = question; RCT = randomized controlled trial; RNA = ribonucleic acid.

Note: If all items are answered "yes" or "unclear," then the study is included.

^a Discuss with a second reviewer.

^b Diagnostic test (PCR) for Q5.